Tisotumab vedotin

Overview

Tisotumab vedotin is an antibody-drug conjugate (ADC) used in the treatment of certain types of cancer. It is designed to deliver a cytotoxic agent directly to tumor cells by targeting the tissue factor (TF) antigen, which is overexpressed in various malignancies.

Mechanism of Action

Tisotumab vedotin consists of a monoclonal antibody that specifically binds to tissue factor, linked to a potent cytotoxic agent, monomethyl auristatin E (MMAE). Upon binding to the tissue factor on the surface of cancer cells, the ADC is internalized, and MMAE is released inside the cell, leading to microtubule disruption and subsequent apoptosis of the cancer cell.

File:Vedotin ADCs.svg

Diagram of Vedotin ADCs

Clinical Applications

Tisotumab vedotin is primarily used in the treatment of cervical cancer and is being investigated for use in other cancers such as ovarian cancer, endometrial cancer, and bladder cancer. Its ability to target tissue factor makes it a promising therapeutic option for tumors that express this antigen.

Development and Approval

The development of tisotumab vedotin involved extensive clinical trials to evaluate its safety and efficacy. It has been granted accelerated approval by regulatory agencies for use in patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy.

Side Effects

Common side effects of tisotumab vedotin include nausea, fatigue, alopecia, and peripheral neuropathy. Serious adverse effects can include hemorrhage, ocular toxicity, and neutropenia. Patients receiving this treatment require careful monitoring for these potential complications.

Related Pages

• Antibody-drug conjugate
• Monoclonal antibody
• Cancer treatment
• Cervical cancer